伐地那非是一种高选择性的新型磷酸二酯酶5抑制剂，是广泛ED人群的一线治疗药物。
Vardenafil, a novel and highly selective phosphodiesterase 5 inhibitor, is the first line therapy for the broad ED population.
伐地那非是一种新型高选择性磷酸二酯酶5型抑制剂，它对心血管系统的安全性已被多项临床试验所证实。
Vardenafil, as a novel and highly selective phosphodiesterase 5 inhibitor, has been proved by many clinical trials to be quite safe for the cardiovascular system.
在研究中心进行的、固定剂量的伐地那非研究不能完全代表磷酸二酯酶(PDE) 5抑制剂在临床实践中的应用情况。
Since fixed-dose vardenafil clinical trails don t fully represent utilization of phosphodiesterase-5 (PDE5) inhibitor in general clinical practice.
伐地那非是一种强效、高选择性的5型磷酸二酯酶(PDE5)抑制剂，对PDE5的抑制作用约为西地那非的10倍。
Vardenafil is a potent and highly selective phosphodiesterase type 5 (PDE5) inhibitor with a potency about 10-fold higher than sildenafil.
这项研究是由辉瑞公司发起，分类上称为他达拉非、艾力达或伐地那非，主要由葛兰素史克公司，拜耳公司和先灵葆雅公司销售，工作方式与伟哥类似。
The research was funded by Pfizer Inc, known generically as tadalafil, and Levitra or vardenafil, sold by GlaxoSmithKline, Bayer ag and Schering-Plough, work in a similar way to Viagra.
这项研究是由辉瑞公司发起，分类上称为他达拉非、艾力达或伐地那非，主要由葛兰素史克公司，拜耳公司和先灵葆雅公司销售，工作方式与伟哥类似。
The research was funded by Pfizer Inc, known generically as tadalafil, and Levitra or vardenafil, sold by GlaxoSmithKline, Bayer ag and Schering-Plough, work in a similar way to Viagra.
应用推荐